GlassScriptPhysician profile
Fawaz Abdrabbo
NPI 1760466551
$4,360.23
in general payments reported to CMS, 2019-2025
23 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $362 · 2020: $293 · 2021: $1,086 · 2022: $902 · 2023: $693 · 2024: $556 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,193.77 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $645.81 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $526.83 | 2020-2024 | Trintellix |
| Axsome Therapeutics, INC. | $301.64 | 2022-2024 | Sunosi, Auvelity |
| Lundbeck LLC | $282.70 | 2019-2024 | Rexulti |
| Allergan, INC. | $219.19 | 2019-2020 | |
| Eisai INC. | $151.52 | 2020-2021 | |
| Vanda Pharmaceuticals INC. | $126.81 | 2019-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $115.47 | 2021-2025 | Qelbree, Qelbree |
| Teva Pharmaceuticals USA, INC. | $114.83 | 2022-2024 | Austedo, Austedo Xr |
| Idorsia Pharmaceuticals US INC | $110.40 | 2022-2023 | Quviviq |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.62 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $95.14 | 2020-2024 | |
| Jazz Pharmaceuticals INC. | $92.98 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $74.53 | 2025 | Cobenfy |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $59.94 | 2023-2025 | Ingrezza |
| Merck Sharp & Dohme LLC | $36.02 | 2021-2022 | |
| Corium, LLC | $28.69 | 2025 | Azstarys |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.16 | 2025 | |
| Collegium Pharmaceutical, INC. | $16.10 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $15.97 | 2022 | |
| Adlon Therapeutics L.P. | $13.99 | 2020 | |
| Bausch Health US, LLC | $13.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fawaz Abdrabbo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.